News and Events

Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy

A finding published in Cell Reports holds promise for resolving some of the conundrums surrounding CD4+ T cells and their potential in fighting cancer. The work found that CD4+ T-cell responses to tumor antigens are quite different from those to infections, highlighting a need to re-think how to harness the power of CD4+ T cells.

Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy

New findings hint at therapies for African Americans with lung cancer

A study published in Nature Communications reveals that two genes tend to be mutated at higher rates in cancerous lung tissue samples taken from African Americans, hinting that these patients may benefit more from certain therapies targeting those genes.

Christopher Buck recently featured in Nature Index article

Christopher Buck, Ph.D., Senior Investigator in the Laboratory of Cellular Oncology, was recently featured in a Nature Index article where he discussed US-China scientific relations and how collaboration between the two remains strong.

Ronald Gress discusses therapeutic potential of supercentinarian immune cells

Ronald Gress, M.D., Chief of the Experimental Transplantation and Immunotherapy Branch, was recently featured in a Forbes article about a unique feature of the immune system of supercentenarians—an increased frequency of certain subset of CD4 T-cells that could play a role in the longevity of these individuals. Dr. Gress discussed several important questions that must be investigated to understand the therapeutic potential of these T-cells.

Martha Zeiger elected President of the American Thyroid Association

Martha Zeiger, M.D., Head of the Surgical Oncology Program, was recently elected President of the American Thyroid Association (ATA) and received the association’s 2019 Lewis E. Braverman Distinguished Award. The award is presented annually to an individual who demonstrates excellence and passion for mentoring fellows, students and junior faculty, has a long history of productive thyroid research and is devoted to the ATA.

Newest Lasker Scholars Nirali Shah and David Takeda featured in Intramural Research Program blog

Nirali Shah, M.D., M.H.Sc., Investigator in the Pediatric Oncology Branch, and David Takeda, M.D., Ph.D., Investigator in the Laboratory of Genitourinary Cancer Pathogenesis, are two of the five physician-scientists selected as the 2019 class of Lasker Clinical Research Scholars. In a recent Intramural Research Program blog, they discuss their research and how the resources at NCI and NIH have helped support their goals.

POSTPONED: RNA Imaging and Intracellular Dynamics Workshop

RNA biology has emerged as one of the most influential areas in modern biology and biomedicine. The NCI is home to a wide spectrum of work in RNA biology ranging from elucidating RNA biogenesis and structure, identifying functions for various classes of RNAs, establishing the role of RNA in disease and exploring RNA-based and RNA-targeted therapies.

This workshop will focus on how basic steps in RNA metabolism are carried out and are integrated into a complex intracellular environment. It aims to bring together experts in the field to describe recent advances in methodologies used to understand subcellular RNA distribution, organization and function, discuss the impact they have had on current models and identify key areas of future development.

POSTPONED: 3rd NCI Symposium on Cancer Health Disparities

Cancer health disparities affect millions of people across the United States. Disparities in cancer burden are evident by geography, race/ethnicity, genetic ancestry, immigrant status, culture, gender, sexual orientation (LGBTQ+) and socioeconomic class, among other factors. The 3rd NCI Symposium on Cancer Health Disparities will present recent advances in our understanding of the causes of cancer health disparities in rural populations and among Native Americans, focus on the roles of financial toxicity and the tumor immune profile in causing outcome disparities and discuss evidence-based strategies to reduce these disparities, including novel approaches to prevention and precision medicine.

Jonathan Hernandez named one of Washington, D.C.’s best doctors

Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, has been selected as one of Washington, D.C.’s 2019 top doctors by The Washingtonian. Top Doctors are selected by nearly 13,000 doctors in D.C., Maryland and Virginia who name a colleague they would recommend in a variety of specialties.

Breadcrumb